Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response

Table 2 Treatment details of combination regimens

Regimen	Drug 1	Drug 2	Drug 3
2	S-1 (6.9 mg/kg, po, qd*14)	Oxaliplatin (5 mg/kg, ip, qw)	NA
3	Capecitabine (400 mg/kg, po, qd*14)	Oxaliplatin (5 mg/kg, ip, qw)	NA
4	Capecitabine (400 mg/kg, po, qd*14)	Oxaliplatin (5 mg/kg, ip, qw)	Epirubicin (5 mg/kg, ip, qw)
5	Cisplatin (5 mg/kg, ip, qw)	5-FU (15 mg/kg, ip, qd*5)	Docetaxel (20 mg/kg, ip, qw)
7	Gemzar (60 mg/kg, ip, q4d)	Cisplatin (5 mg/kg, ip, qw)	NA
12	Oxaliplatin (5 mg/kg, ip, qw)	Irinotecan (40 mg/kg, ip, q4d)	NA

Drug combinations used to test efficacy in PDX models, including detailed treatment conditions in brackets (); Combination regimens have the same numbering as Table 3
NA not available, po per os, ip intraperitoneal, qd once a day, biw twice a week, qw once a week, q4d once every 4 days

ISSN: 2523-3548